tert-butyl 4-(3,5-dichlorophenoxy)piperidine-1-carboxylate | 254883-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(3,5-dichlorophenoxy)piperidine-1-carboxylate
• 英文别名: N-tert-butoxycarbonyl-4-(3,5-dichlorophenoxy)piperidine
• CAS: 254883-38-0
• 化学式: C₁₆H₂₁Cl₂NO₃
• 分子量: 346.254
• InChiKey: CLFHHFSIHKYIKC-UHFFFAOYSA-N

物化性质

• 沸点：
  428.6±45.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3,5-dichlorophenoxy)piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-(3,5-dichlorophenoxy)piperdine
  参考文献：
  名称：

  Efflux pump inhibitors

  摘要：

  描述了具有外流泵抑制剂活性的化合物。还描述了使用这种外流泵抑制剂化合物的方法以及包括这种化合物的药物组合物。

  公开号：

  US06399629B1
• 作为产物：
  描述：

  3,5-二氯苯酚 、 N-Boc-4-羟基哌啶 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 36.0h， 以64%的产率得到tert-butyl 4-(3,5-dichlorophenoxy)piperidine-1-carboxylate
  参考文献：
  名称：

  WO2007/1975

  摘要：

  公开号：

文献信息

• [EN] SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF<br/>[FR] BENZAMIDES SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2015078374A1

  公开（公告）日：2015-06-04

  The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  这项发明提供了具有一般式I的化合物及其药用盐，其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述，并包含这种化合物的组合物和使用这种化合物和组合物的方法。
• Efflux pump inhibitors
  申请人：Microcide Pharmaceuticals, Inc.

  公开号：US06399629B1

  公开（公告）日：2002-06-04

  Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.

  描述了具有外流泵抑制剂活性的化合物。还描述了使用这种外流泵抑制剂化合物的方法以及包括这种化合物的药物组合物。
• SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
  申请人：GENENTECH, INC.

  公开号：US20150252038A1

  公开（公告）日：2015-09-10

  The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R A , R AA , subscript n, ring A, X 2 , L, subscript m, X 1 , R 1 , R 2 , R 3 , R 4 , R 5 , and R N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compactions.

  本发明提供具有一般式I的化合物及其药学上可接受的盐，其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述，并且包含这些化合物的组合物和使用这些化合物和组合物的方法。
• Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
  申请人：Aslanian G. Robert

  公开号：US20070015807A1

  公开（公告）日：2007-01-18

  Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M 1 and M 3 are CH or N; M 2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH 2 ) q —, —C(═NOR 7 )— or —SO 1-2 —; Z is a bond or optionally substituted alkylene or alkenylene; R 1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R 2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R 3 is H, —C(O)NH 2 , or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.
• HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS
  申请人：Aslanian Robert G.

  公开号：US20090286830A1

  公开（公告）日：2009-11-19

  Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M 1 and M 3 are CH or N; M 2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH 2 ) q —, —C(═NOR 7 )— or —SO 1-2 —; Z is a bond or optionally substituted alkylene or alkenylene; R 1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R 2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R 3 is H, —C(O)NH 2 , or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.